

Abe T, Abe T, Ageta S, Kakuta T, Suzuki N, Hirata H, Shouno M, Saio H, Akizawa T: A New Method for Removal of Albumin-Binding Uremic Toxins: Efficacy of an Albumin-Dialysate. **International Society for Apheresis** 2001; 5(1):58–63.

Abe T, Uchita K, Orita H, Kamimura M, Oda M, Hasegawa H, Kobata H, Fukunishi M, Shimazaki M, Abe T, Akizawa T, Ahmad S: Effect of beta2-microglobulin adsorption column on dialysis-related amyloidosis. **Kidney Int** 2003;64: 1522–1528.

Abreo K, Sella M, Gautreaux S, et al ., p-cresol phenol increase the uptake and toxicity of aluminum in cultured mouse hepatocytes. **J Am Nephrol** 1997; 8:935.

Abuelo JG, Schwartz ST, Reginato AJ: Cutaneous oxalosis after long-term hemodialysis. **Arch Intern Med** 1992;152:1517–1520.

Aebersold R and Mann M: Mass spectrometry-based proteomics. **Nature** 2003;422: 198 –207.

Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. **Kidney Int** 2004; 65: 2279_89.

Agodoa LYC, Held PJ, Port FK: U.S. Renal Data System Annual Data Report, 7th ed. Springfield, VA: **National Technical Information Service**, 1997.

Arici M and Walls J. End-stage renal disease, atherosclerosis and cardiovascular mortality: is C- reactive protein the missing link? **Kid Int** 2001; 58(1): 407-414.

Axelsson J, Bergsten A, Qureshi AR et al., Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. **Kidney Int** 2006; 69:596-604.

Bachmann j, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, Zidek W. Recent progress in the analysis of uremic toxins by mass spectrometry. **J. Am. Soc. Nephrol.** 1995; 6:121.

Bammens B, Evenepoel P, Keuleers H. et al., Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. **Kidney International** 2006; 69, 1081–1087.

Bammens B, Evenepoel P, Verbeke K et al., Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. **Kidney Int** 2003; 64: 2238–2243.

Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y: Removal of the protein bound solute p-cresol by convective transport: a randomized crossover study. **Am J Kidney Dis** 2002; 44:278–285.

Bellomo R, Tipping P, Boyce N: Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. **Crit Care Med** 1993; 21:522–527.

Bergstroöm J. “Uremic toxicity” In Nutritional Management of Renal Disease, Kopple J D, Massry S G, Eds; Williams & Wilkins: Baltimore 1997; 97 – 190.

Bisse E, Huaman GP, Horth P, Busse GA, Lizama M, Kramer GA, Haehnel W, Wieland H. “Heterogeneity of hemoglobin A1d: assessment and partial characterization of two new minor hemoglobins, A1d3a and A1d3b, increased in uremic and diabetic patients, respectively.” *J Chromatogr B* 1996; 687: 349 – 356.

Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk end-stage renal disease. *Hypertension* 2001; 38: 938–942.

Blankenberg S, Luc G, Ducimetiere P, et al., PRIME Study Group: Interleukin-18 and the risk of coronary heart disease in European men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME). *Circulation* 2003;108 : 2453 –2459.

Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum J, Zeig S, Slatopolsky E. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. *Am J Kidney Dis.* 1999; 33(4): 694–701.

Bode-Boger SM, Scalera F, Kielstein JT, et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. *J Am Soc Nephrol* 2006; 17:1128-1134.

Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft PC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. **Am J Kidney Dis** 1996; 27: 394–401.

Bright R: Cases and observations, illustrative of renal disease accompanied by the secretion of albuminous urine. **Guy's Hosp Rep** 1836;1:338–380.

Brook NR and Nicholson ML : kidney transplantation from non heart-beating donors. **Surgeon**; 2003; 1(6): 311-322.

Canada USA (CANUSA) Peritoneal Dialysis Study Group: Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes. **J Am Soc Nephrol** 1996; 7:198–207.

Canaud B. What is the evidence that large toxins enhance morbidity and mortality? ,powerpoint presentation from 26th Annual Dialysis Conference , San Francisco , Feb. 2006.

Canaud B, Bragg-Gresham JL, Marshall MR Desmeules S, Gillespie BW, Depner T: Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. **Kidney International** 2006; 69, 2087–2093.

Cardounel AJ, Cui H, Samouilov A, et al., Evidence for the pathophysiological role of endogenous methylarginines in regulation of

endothelial NO production and vascular function. **J Biol Chem.** 2007;12:879–887.

Cascalho M and Platt JL: xenotransplantation and other means of organ replacement. **Nat Rev Immunol** 2001; 1:154-160.

Charra B, Calemard E, Laurent G: Importance of treatment time and blood pressure control in achieving long-term survival on dialysis. **Nephron**1996; 16:35–44.

Charra B, Calemard E, Ruffe M, Chazot C, Terrat JC, Vanel T, Laurent G: Survival as an index of adequacy of dialysis. **Kidney Int** 1992; 41:1286–1291.

Chelamcharla M, Leypoldt JK, Cheung AK. Dialyzer membranes as determinants of the adequacy of dialysis. **Semin Nephrol** 2005; 25: 81–89.

Chen HC, Tsai JC, Tsai JH, Lai YH. Recombinant human erythropoietin enhances superoxide production by FMLP stimulated polymorphonuclear leukocytes in hemodialysis patients. **Kidney Int** 1997; 52: 1390_4.

Chertow GM, Burk SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. **Kidney Int** 2002; 62 (1): 245-252.

Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck GJ, Clark W, Levey AS, Ornt DB,

Schulman G, Schwab S, Teehan B, Eknoyan G: Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. **J Am Soc Nephrol** 2006;17(2):546–555.

Chu J, Yuan Z, Liu X, Wu Q, Mi H, He B. Recent progress in the analysis of uremic toxins by mass spectrometry. **Clin Chim Acta** . 2001; 311: 95.

Clark WR and Gao D: Low-molecular weight proteins in end-stage renal disease: potential toxicity and dialytic removal mechanisms. **J Am Soc Nephrol** 2002;13:S41–S47.

Coburn JW and Salusky IB: Control of serum phosphorus in uremia. **N Engl J Med** 1989; 320:1140–1142.

Coen G, Manni M, Mantella D et al., Are PTH serum levels predictive of coronary calcifications in hemodialysis patients? **Nephrol Dial Transplant**. 2007; 22(11): 3262-7.

Cohen G, Glorieux G, Thornally P et al . review on uremic toxins III: recommendations for handling Uremic retention solutes in vitro towards a standardized approach for research on uremia. **Nephrol Dial Transplant** 2007; 22:3381-390.

Cohen G and Horl WH: Retinol binding protein isolated from acute renal failure patients inhibits polymorphonuclear leucocyte functions. **Eur J Clin Invest** 2004; 34:774–781.

D'Amour P, Jobin J, Hamel LL, 'Ecuyer N: iPTH values during

hemodialysis: Role of ionized Ca, dialysis membranes and iPTH assays. **Kidney Int**1990; **38**:308–314.

D’Hooge R, Van de Vijver G, Van Bogaert PP, Marescau B, Vanholder R, De Deyn PP: Involvement of voltage- and ligand-gated Ca²⁺ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins. **Kidney Int** 2003; **63**:1764–1775.

De Deyn PP, Robitaille P, Vanasse M, Qureshi IA, Marescau B: Serum guanidino compound levels in uremic pediatric patients treated with hemodialysis or continuous cycle peritoneal dialysis. **Nephron** 1995; **69**:411–417.

De Loor H, Bammens B, Evenepoel P, De Preter V, Verbeke K. Recent progress in the analysis of uremic toxins by mass spectrometry. **Clin. Chem.** (2005); **51**: 1535.

De Smet D, Dhondt A, Eloot S, Galli F et al., Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein bound and protein-bound uraemic solutes. **Nephrol Dial Transplant** 2007; **22**: 2006–2012.

Deguchi T, Isozaki K, Yousuki N et al., Involvement of organic anion transporters in the efflux of uremic toxins across the blood-brain barrier. **J Neurochem.** 2006;**96**(4):1051-9.

Depner TA: Benefits of more frequent dialysis: lower TAC at the same Kt/V. **Nephrol Dial Transplant** 1998;**13**:20–24.

Depner TA, Nephrology Division, Department of Medicine, University of California, Davis, Davis, California. **Seminars in Dialysis—Vol 14, No 4 (July–August) 2001; pp. 246–251.**

Depner T. Hemodialysis adequacy: basic essentials and practical points for the nephrologists in training. **Hemodial Int 2005; 9: 241-254.**

Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P: The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. **Kidney Int 2004; 65:442– 451.**

Dou L, Cerini C, Brunet P et al. p-Cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. **Kidney Int 2002; 62: 1999–2009.**

Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, Dignat-George F, Brunet P: The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. **J Thromb Haemost 2007; 5:1302–1308.**

Druke T, Witko-Sarsat V, Massy Z et al., Iron therapy, advanced oxidation protein products and carotid artery intima-media thickness in end-stage renal disease. **Circulation 2002; 106:2212-2217.**

Dzurik R, Spustova V, Krivosikova Z, Gazdikova K: Hippurate participates in the correction of metabolic acidosis. **Kidney Int 2001;78(Suppl):S278–281.**

Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R: Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. **N Engl J Med** 2002;347:2010–2019.

Eschbach JW : the anemia of chronic renal failure : pathophysiology and the effect of recombinant erythropoietin. **Kidney Int** 1989; 35:134-148.

Fagugli RM, De Smet R, Buon cristiani U, Lameire N, Vanholder R: Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. **Am J Kidney Dis** 2002;40:339–347.

Faure V, Dou L, Sabatier F, Cerini C, Sampol J, Berland Y, Brunet P, Dignat-George F: Elevation of circulating endothelial microparticles in patients with chronic renal failure. **J Thromb Haemost** 2006; 4: 566 –573.

Feliciani A, Riva MA, Zerbi S et al., New strategies in haemodiafiltration (HDF): prospective comparative analysis between on-line mixed HDF and mid-dilution HDF. **Nephrol Dial Transplant** 2007; 22: 1672–1679.

Fenton SS, Schaubel DE, Desmeules M, Morrison HI, Mao Y, Copleston P, Jeffery JR, Kjellstrand CM: Hemodialysis versus peritoneal dialysis: A comparison of adjusted mortality rates. **Am J Kidney Dis** 1997; 30:334–342.

Fissel WH and Humes HD: Cell therapy of renal failure. **Transplant Proc** 2003; 35: 2837-2842.

Fujimori A, Naito H, Miyazaki T. Adsorption of complement, cytokines, and proteins by different dialysis membrane materials: evaluation by confocal laser scanning fluorescence microscopy. **Artif Organ.** 2006; 22(12): 1014–7.

Furuichi K, Wada T, Iwata Y, Kokubo S, Hara A, Yamahana J, Sugaya T, Iwakura Y, Matsushima K, Asano M, Yokoyama H, Kaneko S: Interleukin-1-dependent sequential chemokine expression and inflammatory cell infiltration in ischemia-reperfusion injury. **Crit Care Med** 2006; 34:2447–2455.

Galli F, Benedetti S, Buoncristiani U, Piroddi M, Conte C, Canestrari F, Buoncristiani E, Floridi A: The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels. **Kidney Int** 2003;64: 748 –755.

Ganesh SK, Halbert-Sheron T, Port FK et al. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. **J Am Soc Nephrol** 2003; 14: 415-424.

Garg, J.P., Chasan-Taber, S., Blair, A., Plone, M., Bommer, J., Raggi, P., Chertow, G.M. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. **Arthritis Rheum.** 2005;52 (1), 290–295.

Gejyo F and Brancaccio D. “ β_2 -microglobulin: a possible new uremic toxin?” **Int J Artif Organs** 1988, **11**: 3 – 5.

Glassock Richard J .Uremic toxins: what are they? An Integrated Overview of Pathophysiology and Classification. **Journal of Renal Nutrition** 2008; **18**(1):2-6.

Glorieux G, Helling R, Henle T, Brunet P, Deppisch R, Lameire N, Vanholder R: In vitro evidence for immune activating effect of specific AGE structures retained in uremia. **Kidney Int** 2004a;**66**: 1873–1880.

Glorieux GL, Dhondt AW, Jacobs P, Van Langeraert J, Lameire NH, De Deyn PP, Vanholder RC: In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. **Kidney Int** 2004b;**65**:2184–2192.

Grzegorzewska AE and Mlot-Michalska M. Bone pain in dialysis patients is not associated with bone mineral density but with serum concentration of small uremic toxins. **Advances in Medical Sciences** 2007; **52**:228-31.

Gueler F, Gwinner W, Schiborr C et al. Biocompatibility parameters of different dialysis membranes assessed during systemic inflammation. **Blood Purif** 2005; **23**: 196–202.

Gupta A and Robinson K : Hyperhomocysteinemia and end stage renal disease. **J Nephrol** 1997;**10**:77-84.

Gutzwiller JP, Schneditz D, Huber AR, et al. Increasing blood flow increases $kt/V(\text{urea})$ and potassium removal but fails to improve phosphate removal. **Clin Nephrol** 2003; 59:130–6.

Haaber AB, Eidemak I, Jensen T, Feldt-Rasmussen B, Strandgaard S: Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure. **J Am Soc Nephrol** 1995; 5: 1581–1584.

Haase M, Bellomo R, Baldwin I, Haase-Fielitz A, Fealy N, Davenport P, Morgera S, Goehl H, Storr M, Boyce N, Neumayer HH: Hemodialysis membrane with a high-molecular weight cutoff and cytokine levels in sepsis complicated by acute renal failure: A phase 1 randomized trial. **Am J Kidney Dis** 2007;50: 296 –304.

Hanly PJ, Gabor JY, Chan C et al., Daytime sleepiness in patients with CRF: impact of nocturnal hemodialysis. **Am J Kidney Dis.** 2003;41(2):403-10.

Heaf J and Jensen S: Normalized cellular clearance of creatinine, urea and phosphate. **Nephron** 1994; 67:197–202.

Herbrig K, Pistrosch F, Oelschlaegel U, Wichmann G, Wagner A, Foerster S, Richter S, Gross P, Passauer J: Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis. **Am J Kidney Dis** 2004; 44: 840 – 849.

Herget-Rosenthal S, Glorieux G, Jankowski J, et al. Germany, Department of Internal Medicine, Renal Division, Gent University Hospital, Gent, Belgium, and Charite´ ,Universita¨ tsmedizin Berlin, Medizinische Klinik IV, Berlin, **Germany Seminars in Dialysis—Vol 22, No 4 (July–August) 2009; pp. 445–448.**

Hernandez-Borges J, Neususs C, Cifuentes A, Pelzing M: On-line capillary electrophoresis-mass spectrometry for the analysis of biomolecules. **Electrophoresis 2004;25: 2257–2281.**

Herring KD, Oppenheimer SR, Caprioli RM. Recent progress in the analysis of uremic toxins by mass spectrometry. **Semin. Nephrol. 27 2007; 597.**

Himmelfarb J, Chuang P, Schulman G. Chapter 58: Hemodialysis, Barry M. Brenner. **Brenner & Rector's the kidney 8th edition 2008; p 1957-2006.**

Himmelfarb J, McMonagle E, Freedman S, Klenzak J, McMennamin E, Le P, Pupim LB, Ikizler TA: Oxidative stress is increased in critically ill patients with acute renal failure. **J Am Soc Nephrol 2004;15:2449– 2456.**

Horl WH. Genesis of the uraemic syndrome: **role of uraemic toxins.** 1998; 110: 511–520.

Honda K, Nitta K, Horita S et al., Accumulation of advanced glycation end-products in the peritoneal vasculature of continuous ambulatory

peritoneal dialysis patients with low ultra-filtration. **Nephrol Dial Transplant** 1999;14:1541-1549.

Humes HD, Buffington DA, MacKay SM, Funke AJ, Weitzel WF: Replacement of renal function in uremic animals with a tissue-engineered kidney. **Nat Biotechnol** 1999b;17: 451– 455.

Humes HD, Fissell WH and Tiranathanagul K. The future of hemodialysis membranes. **Kidney Int** 2006; 69, 1115–1119.

Humes HD, MacKay SM, Funke AJ, Buffington DA: Tissue engineering of a bioartificial renal tubule assist device: In vitro transport and metabolic characteristics. **Kidney Int** 1999a;55: 2502–2514.

Humes HD, Weitzel WF, MacKay SM, Fissell WH, and Gutierrez JM. Metabolic replacement of kidney function in uremic animals with a bioartificial kidney containing human cells. **Am J Kidney Dis** 2002;39:1078-1087.

Humes HD, Weitzel WF, Bartlett RH, Lderer JR, and Sobota J. Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. **Kidney Int** 2004; 66: 1578-1588.

Ifudo O, Feldman J, Friedman EA: The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. **N Engl J Med** 1996; 334:420-425.

Iseki K, Fukiyama K. Long-term prognosis and incidence of acute myocardial infarction in patients on chronic hemodialysis. The Okinawa Dialysis Study Group. **Am J Kidney Dis** 2000;36:820–5.

Iwasaki Y, Yamato H, Fujieda T et al., Uremic toxin and bone metabolism. **J Bone Miner Metab** 2006;24:172–175.

Iwasaki-Ishizuka Y, Yamato H, Nii-Kono T et al., Skeletal resistance to PTH is induced by indoxyl sulfate, one of the uremic toxins, leading to adynamic bone.

Iwata K, Watanabe H, Morisaki T, Matsuzaki T, Ohmura T, Hamada A, Saito H: Involvement of indoxyl sulfate in renal and central nervous system toxicities during cisplatin-induced acute renal failure. **Pharm Res** 2007; 24:662–671.

Jaber BL, Zimmerman DL, Teehan GS et al., Daily hemofiltration for end-stage renal disease: a feasibility and efficacy trial. **Blood Purif** 2004;22:481-489.

Jaconi S, Rose K, Huhes GJ, Saurat JH, Siegenthaler G. “Characterization of two post-translationally processed forms of human serum retinol-binding protein: altered ratios in chronic renal failure.” **J Lipid Res** 1995; 36, 1247 – 1253.

Jadoul M, Garbar C, Vanholder R, et al., Prevalence of histological β 2-microglobulin amyloidosis in CAPD-patients. Comparison with HD patients. **Kidney Int** 1998; 54:956.

Jager KJ, Korevaar JC, Dekker FW, et al. The effect of contraindications and patient preference on dialysis modality selection in ESRD patients in The Netherlands. **Am J Kidney Dis** 2004;43(5): 891-899.

Jankowski J, Hagemann J, Yoon MS, van der Giet M, Stephan N, Zidek W, Schluter H, Tepel M: Increased vascular growth in hemodialysis patients induced by platelet-derived diadenosine polyphosphates. **Kidney Int** 2001; 59: 1134 –1141.

Jankowski J, Jankowski V, Laufer U, van der Giet M, Henning L, Tepel M, Zidek W, Schluter H: Identification and quantification of diadenosine polyphosphate concentrations in human plasma. **Arterioscler Thromb Vasc Biol** 2003;23: 1231–1238.

Jankowski V, Karadogan S, Vanholder R, Nofer JR, Herget-Rosenthal S, van der Giet M, Tolle M, Tran TN, Zidek W, Jankowski J: Paracrine stimulation of vascular smooth muscle proliferation by diadenosine polyphosphates released from proximal tubule epithelial cells. **Kidney Int** 2007b; 71: 994 –1000.

Jankowski V, Tolle M, Vanholder R et al., Uridine adenosine tetraphosphate: a novel endothelium-derived vasoconstrictive factor. **Nat Med** 2005; 11:223-227.

Jankowski V, Vanholder R, Van Der Giet M et al., Mass-spectrometric identification of a novel angiotensin peptide in human plasma. **Arterioscler Thromb Vasc Biol** 2007a; 27:297-302.

Johannesson N, Wetterhall M, Markides KE, Bergquist J: Monomer surface modifications for rapid peptide analysis by capillary electrophoresis and capillary electrochromatography coupled to electrospray ionization-mass spectrometry. **Electrophoresis** 2004;25: 809 – 816.

Johnson WJ, Hagge WW, Wagoner RD, Dinapoli RP, Rosevear JW: Effects of urea loading in patients with far-advanced renal failure. **Mayo Clin Proc** 1972; 47:21–29.

Kaiser T, Hermann A, Kielstein JT et al. Capillary electrophoresis coupled mass spectrometry to establish polypeptide patterns in dialysis fluids. **J Chromatography A** 2003; 1013: 157–171.

Kanu AB, Dwivedi P, Tam M, Matz L, Hill Jr. Recent progress in the analysis of uremic toxins by mass spectrometry. **J. Mass Spectrom.** 43 2008; 1.

Kato A, Odamaki M, Hishida A. Association between blood indoxyl sulfate and carbonyl stress marker in hemodialysis patients. **Clin Nephrol** 2003; 60: 161–167.

Kaysen GA. The microinflammatory state in uremia: causes and potential consequences. **J Am Soc Nephrol** 2001;12(7): 1549-1557.

Kaysen GA, Dubin JA, Müller H-G, Mitch WE, Rosales LM, Levin NW: Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. **Kidney Int** 2002;61: 2240 –2249.

Keshaviah P, Nolph KD, Van Stone J: The peak concentration hypothesis: A urea kinetic approach to comparing the adequacy of continuous ambulatory peritoneal dialysis and hemodialysis. **Perit Dial Int** 1989; 9:257–260.

Khuroo M, Khuroo MS, Farahat K: Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. **Liver Transpl** 2004;10:1099–1106.

Kielstein JT, Boger RH, Bode-Boger SM, Martens-Lobenhoffer J, Lonnemann G, Frolich JC, Haller H, Fliser D: Low dialysance of asymmetric dimethylarginine (ADMA) – in vivo and in vitro evidence of significant protein binding. **Clin Nephrol** 2004; 62:295–300.

Kim DJ, Do JH, Huh W, Kim YG, Oh HY: Dissociation between clearances of small and middle molecules in incremental peritoneal dialysis. **Perit Dial Int** 2001;21:462–466.

Kishimoto TK, Viswanathan K, Ganguly T: contaminated heparin associated with adverse clinical events and activation of the contact system. **N Engl J Med** 2008;358(23): 2457-67.

Kislinger T, Humeny A, Pischetsrieder M. Recent progress in the analysis of uremic toxins by mass spectrometry. **Curr. Med. Chem.** 11 2004; 2185.

Klampfl CW: Recent advances in the application of capillary electrophoresis with mass spectrometric detection. **Electrophoresis** 2006; 27: 334.

Klein CL, Hoke TS, Fang WF, Altmann CJ, Douglas IS, Faubel S: Interleukin-6 mediates lung injury following ischemic acute kidney injury or bilateral nephrectomy. **Kidney Int** 2008; **74**:901–909.

Knepper AM: Proteomics and the Kidney. **J Am Soc Nephrol** 2002;**13**: 1398 1408.

Koc M, Richards HB, Bihorac A, et al. Circulating endothelial cells are associated with future vascular events in hemodialysis patients. **Kid Int** 2005; **67**(3): 1078-1083.

Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, Sakai S, Yuasa Y, Hirasawa Y, Nishi T. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. **Kidney Int** 1997;**52**(4):1096–1101.

Kolch W, Neususs C, Pelzing M, Mischak H: Capillary electrophoresis mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. **Mass Spectrom Rev** 2005;**24**: 959 –977.

Komatsu S, Zang X, Tanaka N: Comparison of two proteomics techniques used to identify proteins regulated by gibberellin in rice. **J Proteome Res** 2006;**5**: 270 –276.

Krane V, Krieter DH, Olschewski M, Marz W, Mann JF, Ritz E, Wanner C. Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. **Am J Kidney Dis** 2007;**49**(2):267–275.

Krieter DH, Canaud B: High permeability of dialysis membranes: What is the limit of albumin loss? **Nephrol Dial Transplant** 2003;18: 651– 654.

Krishnan AV, Phoon RK, Pussel BA et al., Altered motor nerve excitability in end-stage kidney disease. **Brain** 2005;128:2164-74.

Lameire N, Van Biesen W, Vanholder R: Acute renal failure. **Lancet** 2005;365:417–430.

Langsdorf LJ, Zydney AL: Effect of uremia on the membrane transport characteristics of red blood cells. **Blood** 1993;81:820–827.

Lanza RP, Chung HY, Yoo JJ, Schuch G, Soker S, Moraes CT. Generation of histocompatible tissues using nuclear transplantation. **Nat Biotechnol** 2002; 20: 689-696.

Le Meur Y, Lorgeot V, Comte L, Szelag JC, Aldigier JC, Leroux Robert C, Praloran V: Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. **Am J Kidney Dis** 2001;38:510–517.

Ledebo I. Principles and practice of hemofiltration and hemodiafiltration. **Artif Organs.** 1998;22(1):20-5.

Lesaffer G, De Smet R, Lameire N, Dhondt A, Duym P, Vanholder R. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. **Nephrol Dial Transplant** 2000;15(1):50–57.

Levillain O, Marescau B, Possemiers I, Al Banchaabouchi M, De Deyn PP: Influence of 72% injury in one kidney on several organs involved in guanidino compound metabolism: a time course study. **Pflugers Arch** 2001; 442:558–569.

Leypoldt JK, Cheung AK, Deeter RB. Rebound kinetics of β_2 -microglobulin after hemodialysis. **Kidney Int.** 1999; 56(4):1571–1577.

Li G, Chu J, Liu X, Yuan Z. Recent progress in the analysis of uremic toxins by mass spectrometry. **Clin. Chim. Acta** 2004; 350: 89.

Li QZ, Xie C, Wu T, Mackay M, Aranow C, Putterman C, Mohan C: Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. **J Clin Invest** 2005;115: 3428–3439.

Lim CF, Bernard BF, de Gong M, et al., A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. **J Clin Endocrinal Metab** 1993; 76:318.

Lim J, Gasson C, Kaji DM: Urea inhibits NaK2Cl cotransport in human erythrocytes. **J Clin Invest** 1995; 96:2126–2132.

Liu M, Liang Y, Chigurupati S, Lathia JD, Pletnikov M, Sun Z, Crow M, Ross CA, Mattson MP, Rabb H: Acute kidney injury leads to inflammation and functional changes in the brain. **J Am Soc Nephrol** 19:1360–1370, 2008.

Llach F: Secondary hyperparathyroidism in renal failure: The trade-

off hypothesis revisited. **Am J Kidney Dis** 1995; 25:663–679.

Locatelli F, Hannedouche T, Jacobson S, La Greca G, Loureiro A, Martin-Malo A, Papadimitriou M, Vanholder R. The effect of membrane permeability on ESRD: design of a prospective randomized multicentre trial. **J Nephrol** 1999;12(2):85–88.

Locatelli F, Martin-Malo A, Hannedouche T : effect of membrane permeability on survival of hemodialysis patients. **J Am Soc Nephrol** 2009; 20.

Loghman-Adham M: Role of phosphate retention in the progression of renal failure. **J Lab Clin Med** 122:16–26, 1993

Lomashvilli KA, Khwandi W, ONeil WC: Reduced plasma pyrophosphate levels in hemodialysis patients. **J Am Soc Nephrol** 2005; 16(8):2495-2500.

London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all causes and cardiovascular compounds such as indoxyl sulfate, indole and p-cresol . **Nephrol Dial Transplant** 2003; 18: 1731–1740.

Lornoy W, Becauss I, Billioux JM, Sierens L, Van Malderen P. Remarkable removal of beta-2-microglobulin by on-line hemodiafiltration. **Am J Nephrol** 1998;18(2):105–108.

Lysaght M, Bruder J, O’Loughlin J. Development of orally administered microcapsules for removal of uremic toxins. **Center for**

Biomedical Engineering, Brown University, Providence, RI , United States. Monday June 2009.

MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E: Concentration of dimethyl-l-arginine in the plasma of patients with end-stage renal failure. **Nephrol Dial Transplant** 1997; 11:2449–2452.

Macdougall IC: Role of uremic toxins in exacerbating anemia in renal failure. **Kidney International. Vol 59, Suppl 2001; 78: pp.S-67-S-72.**

Maduell F, Navarro V, Torregrosa E, Rius A, Dicenta F, Cruz MC, Ferrero JA: Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration. **Kidney Int** 2003;64: 305–313.

Mahiout A, Ehlerding G, Brunkhorst R: Advanced glycation end-products in the peritoneal fluid and in the peritoneal membrane of continuous ambulatory peritoneal dialysis patients. **Nephrol Dial Transplant** 1996;11(Suppl 5):2-6.

Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM Barth RH, Winston JA, Fuh H, Manogue KR: Reactive glycosylation end products in diabetic uremia and treatment of renal failure. **Lancet** 1994;343:1519–1522.

Malik DJ, Warwick GL, Venturi M et al., Preparation of novel mesoporous carbons for the adsorption of an inflammatory cytokine (IL-1 beta). **Biomaterials** 2004;25:2933–2940.

Marangella M, Bagnis C, Bruno M, Petrarulo M, Gabella P, Linari F: Determinants of oxalate balance in patients on chronic peritoneal dialysis. **Am J Kidney Dis** 21:419–426, 1993.

Marangella M, Vitale C, Petrarulo M, Cosseddu D, Gallo L, Linari F: Pathogenesis of severe hyperoxalemia in Crohn's disease-related renal failure on maintenance haemodialysis: Successful management with pyridoxine. **Nephrol Dial Transplant** 1992; 7:960–964.

Martinez AW, Recht NS, Hostetter TH et al., Removal of p-Cresol Sulphate by Hemodialysis. **J Am Soc Nephrol** 2005; 16:3430-3436.

Masstrangelo F, Locatelli F, Redaelli B: effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. **Kidney Int** 1996; 50 (4): 1293-302.

Massy ZA. Importance of homocysteine, lipoprotein(a) and non-classical cardiovascular risk factors (fibrinogen and advanced glycation end-products) for atherogenesis in uremic patients. **Nephrol Dial Transplant** 2000; 15[Suppl5]: 81-91.

Mathew S, Tustison KS, Sugatani T et al., The Mechanism of phosphorus as a Cardiovascular Risk Factor in CKD. **J Am Soc Nephrol** 2008; first published on April 16.

Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai O, Wada Y, Yasukawa H, Iwami G, Okuda S, Imaizumi T: Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in

experimental hypertension. **Hypertension** 1997;29:242–247.

Matsuzaki T, Watanabe H, Yoshitome K, Morisaki T, Hamada A, Nonoguchi H, Kohda Y, Tomita K, Inui K, Saito H: Downregulation of organic anion transporters in rat kidney under ischemia /reperfusion-induced acute renal failure. **Kidney Int** 2007;71:539–547.

McGonigle RJS, Wallen JD: erythropoitin deficiency and inhibition of erythropoiesis in renal insufficiency . **Kidney Int**1984; 25:437-444.

Means RT , Krantz SB : progress in understanding the pathogenesis of the anemia of chronic disease. **blood** 1992; 80:1639-1647.

Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A: Acute Kidney Injury Network: report of an initiative to Improve outcomes in acute kidney injury. **Crit Care** 2007;11:R 31.

Meinitzer A, Seelhorst U, Wellnitz B, et al. Asymmetrical Dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (The Ludwigshafen Risk and Cardiovascular Health Study). **Clinical Chemistry** 2007;53(2): 273–283.

Melnikov VY, Ecder T, Fantuzzi G, Siegmund B, Lucia MS, Dinarello CA, Schrier RW, Edelstein CL: Impaired IL-18 processing caspase-1-deficient mice from ischemic acute renal failure. **J Clin Invest** 2001;107:1145–1152.

Meyer T, Leeper E, Bartlett D, Depner T, Zhao Lit Y, Robertson C, Hostetter T: Increasing dialysate flow and dialyzer mass transfer area coefficient to increase the clearance of protein bound solutes. **J Am Soc Nephrol** 2004;15:1927–1935.

Meyer TM, Peattie JWT, Miller JD et al., Increasing the Clearance of Protein-Bound Solutes by Addition of a Sorbent to the Dialysate. **J Am Soc Nephrol** 2007;18: 868–874.

Mironova R, Niwa T. Recent progress in the analysis of uremic toxins by mass spectrometry. **J. Chromatogr. B** (2001); 758: 109.

Mischak H, Apweiler R, Banks RE, Conaway M, Coon JJ, Dominizak A, Ehrich JH, Fliser D, Girolami M, Hermjakob H, Hochstrasser DF, et al., Clinical proteomics: A need to define the field and to begin to set adequate standards. **Proteomics Clin Appl** 2007;1: 148 –156.

Moe S M and Sprague S M. Uremic encephalopathy. **Clin Nephrol.** 1994;42: 251–256.

Molina H, Bunkenborg J, Reddy GH, Muthusamy B, Scheel PJ, Pandey A: A proteomic analysis of human hemodialysis fluid. **Mol Cell Proteomics** 2005;4: 637– 650.

Monti JP, Brunet PJ, Berland YF, Vanuxem DC, Vanuxem PA, Crevat AD: Opposite effects of urea on hemoglobin-oxygen affinity in anemia of chronic renal failure. **Kidney Int** 1995;48:827–831.

Monti JP, Gallice P, Crevat A, Murisasco A. “Identification by nuclear magnetic resonance and mass spectrometry of a glucuronic conjugate of hydroxybenzoic acid in normal urine and uremic plasma.” **Clin. Chem.** 1985; 31: 1640 – 1643.

Morena MD, Guo D, Balarishman VS et al., Effect of a novel adsorbent on cytokine responsiveness to uremic plasma. **Kidney Int** 2003;63:1150-1154.

Motojima M, Hosokawa A, Yamato H et al., Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kB and free radicals in proximal tubular cells. **Kidney Int** 2003;63:1671–1680

Moustapha A, Gupta A, Robinson K, Arheart K, Jacobsen DW, Schreiber MJ, Dennis VW: Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. **Kidney Int** 1999;55:1470–1475.

Muntner P, He JA, Stor BC, et al., Traditional and non traditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. **J Am Soc Nephrol.** 2005; 16(2):529-38.

Musante L, Bruschi M, Candiano G, Petretto A, Dimasi N, Del Boccio P, Urbani A, Rialdi A, Ghiggeri GM, Biochem Biophys Res Commun. Recent progress in the analysis of uremic toxins by mass spectrometry. 2006; 349: 668.

Musante L, Candiano G, Petretto A, Bruschi M, Dimasi N, Caridi

G et al., Recent progress in the analysis of uremic toxins by mass spectrometry. **J Am Soc Nephrol**. 18 2007; 18: 799.

Napoleone E, Di Santo A, Amore C, Baccante G, Di Febbo C, Porreca E, De Gaetano G, Donati MB, Lorenzet R: Leptin induces tissue factor expression in human peripheral blood mononuclear cells: A possible link between obesity and cardiovascular risk? **J Thromb Haemost** 2007;5: 1462–1468.

Nemeth I, Turi S, Haszon I, Berczki C. Vitamin E alleviates the oxidative stress of erythropoietin in uremic children on hemodialysis. **Pediatr Nephrol** 2000; 14: 13_7.

Niwa T. Mass spectrometry in the search for uremic toxins: Mass Spectrometry Review, 1997; 16: 307-332.

Niwa T. Recent progress in the analysis of uremic toxins by mass spectrometry. **Journal of Chromatography B** 2009; 877: 2600–2606.

Niwa T, Asada H, Tsutsui S, Miyazaki T: Efficient removal of albumin-bound furancarboxylic acid by protein-leaking hemodialysis. **Am J Nephrol** 1995;15: 463– 467.

Niwa T, Ise M, Miyazaki T, et al., Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uremic rats. **J Am Nephron** 1993; 65:82.

Niwa T, Katsuzaki T, Momoi T, Miyazaki T, Ogawa H, Miyazaki S, Tatemichi N, Takei Y. “Modification of β_2 -m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG

accumulating in uremic serum.” **Kidney Int.**1996; 49: 861 – 867.

Niwa T, Kawagishi I, Ohya N. Recent progress in the analysis of uremic toxins by mass spectrometry.**Clin. Chim. Acta** 1994; 226: 89.

Niwa T, Yazawa T, Kodama T, Uehara Y, Maeda K, Yamada K. Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis. **Nephron.** 1990; 56(3):241–245.

Niwa T, Takeda, N, Tatematsu A, Maeda K. “Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography.” **Clin Chem** 1988; 34: 2264 – 2267.

O’Farrell PH: High resolution two-dimensional electrophoresis of proteins. **J Biol Chem** 1975;250: 4007– 4021.

O’Seaghdha CM and Foley RN. Septicemia, access, cardiovascular disease, and death in dialysis patients. **Perit Dial Int** 2005; 25:534.

Owen WF, Lew NL, Liu Y, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. **N Engl J Med** 329:1001–1006, 1993

Parikh CR, Mishra J, Thiessen-Philbrook H, Dursun B, Ma Q, Kelly C, Dent C, Devarajan P, Edelstein CL: Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. **Kidney Int** 2006; 70:199–203.

Pascual M, Schifferli JZ: Adsorption of complement factor D by polyacrylonitrile dialysis membranes. **Kidney Int 1992; 43:903–911.**

Peco-Antic A, Nastic-Miric D, Popovic-Rolovic M, Adanja G, Kostic M, Paripovic V: Endothelin-1 in acute renal failure. **Ren Fail 1996; 18:553– 556.**

Peng J, Gygi SP: Proteomics: The move to mixtures. **J Mass Spect 2001;36: 1083–1091.**

Perl J, Unruh ML, Chan CT. Sleep disorders in end-stage renal disease: ‘Markers of inadequate dialysis’? **Kidney Int 2006;70:1687-93**

Perna AF, Ingrosso D, Satta E, et al. Plasma protein aspartyl damage is increased in hemodialysis patients: studies on causes and consequences. **J Am Soc Nephrol 2004; 15:2747-2754.**

Piccin A, Murphy WG, Smith OP: Circulating microparticles: Patho- physiology and clinical implications. **Blood Rev 2007; 21: 157–171.**

Pisitkun T, Shen RF, Knepper MA: Identification and proteomic profiling of exosomes in human urine. **Proc Natl Acad Sci U S A 2004;101: 13368 –13373.**

Port FK, Wolfe RA, Hulbert-Shearon TE, et al., Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics:

results from the USRDS Dialysis Morbidity and Mortality Study. **Am J Kidney Dis** 2001;37:276-286.

Pozzoni P, Del Vecchio L, Pontoriero G et al., Long-term outcome in hemodialysis: morbidity and mortality. **J Nephrol.** 2004;17 Suppl 8:S87-95.

Rashid G, Benchetrit S, Fishman D, Bernheim J: Effect of advanced glycation end-products on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells. **Kidney Int** 2004; 66: 1099 –1106.

Reynolds JT, Homel P, Cantey L, Evans E, Harding P, Gotch F, Wuerth D, Finkelstein S, Levin N, Kliger A, Simon DB, Finkelstein FO: A one-year prospective trial of short daily hemodialysis (SDHD): clinical parameters [abstract]. **J Am Soc Nephrol** 2002;13:60A.

Rifai K, Ernst T, Kretschmer U, Bahr MJ, Schneider A, Hafer C, Haller H, Manns MP, Fliser D: Prometheus—a new extracorporeal system for the treatment of liver failure. **J Hepatol** 2003;39:984–990.

Ringoir S. An update on uremic toxins. **Kidney Int Suppl.** 1997;62:S2-4.

Roberts MA, Thomas MC, Fernando D et al., Low molecular weight advanced glycation end-products predict mortality in asymptomatic patients receiving chronic hemodialysis. **Nephrology Dialysis Transplantation** 2006; 21(6): 1611-1617.

Rozga J, Umehara Y, Trofimenko A, Sadahiro T, Demetriou AA: A novel plasma filtration therapy for hepatic failure: preclinical studies. **Ther Apher Dial** 2006;10: 138 –144.

Rutkowski B, Slominska E, Szolkiewicz M, Smolenski RT, Striley C, Rutkowski P, Swierczynski J. Recent progress in the analysis of uremic toxins by mass spectrometry. **Kidney Int. Suppl.** 2003;84: S19.

Saito A, Cho K, Sato N et al., Bioengineered Implantation of Megalin Expressing Cells: A Potential Intracorporeal Therapeutic Model for Uremic Toxin. **J Am Soc Nephrol** 2003;14: 2025–2032.

Salzer WR, Hutchins GM: Cardiac lesions in secondary oxalosis. **Arch Intern Med** 1974; 134:250–252.

Sanatoro A, Ferramosca E, Mancini E et al., Reverse mid-dilution: new way to remove small and middle molecules as well as phosphate with high intrafilter convective clearance. **Nephrol Dial Transplant** 2007;22: 2000-2005.

Sassa T, Matsuno H, Niwa M, Kozawa O, Takeda N, Niwa T, Kumada T, Uematsu T. Recent progress in the analysis of uremic toxins by mass spectrometry. **Arch. Toxicol.** 2000;73: 649.

Sassi AP, Andel F 3rd, Bitter HM, Brown MP, Chapman RG, Espiritu J, Greenquist AC, Guyon I, Horchi-Alegre M, Stults KL: An automated, sheathless capillary electrophoresis-mass spectrometry platform for discovery of biomarkers in human serum. **Electrophoresis** 2005;26: 1500 –1512.

Satoh M, Hayashi H, Watanabe M, Ueda K, Yamato H, Yoshioka T and Motojima M. Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure. **Nephron Exp Nephrol** 2003; **95:e111-118**.

Schepky AG, Bensch KW, Schulz-Knappe P, Forssmann WG: Human hemofiltrate as a source of circulating bioactive peptides: Determination of amino acids, peptides and proteins. **Biomed Chromatogr** 1994;**8**: 90 –94.

Schiller LR, Santa Ana CA, Sheikh MS, Emmett M, Fordtran JS:Effect of the time of administration of calcium acetate on phosphorus binding. **N Engl J Med**1989; **320:1110–1113**.

Scholze A, Jankowski V, Hening L, et al., Phenylacetic acid and arterial vascular properties in patients with chronic kidney disease stage 5 on hemodialysis therapy. **Nephron Clin Pract** 2007; **107:c1-c6**.

Schouten WE, Grooteman MP, van Houte AJ, Schoorl M, van Limbeek J, Nube MJ.Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis. **Nephrol Dial Transplant** 2000;**15**:379–84.

Schulz-Knappe P, Schrader M, Standker L, Richter R, Hess R, Jurgens M, Forssmann WG: Peptide bank generated by large-scale preparation of circulating human peptides. **J Chromatogr A** 1997;**776**: 125–132.

Schwarz U, Buzello M, Ritz E et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. **Nephrol Dial Transplant** 2000; 15: 218–223.

Schwedler SB, Metzger T, Schinzel R et al., Advanced glycation end products and mortality in hemodialysis patients. **Kidney Int** 2002; 62:301-310.

Sciffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. **Nephrol Dial Transplant** 2002;17:1814-8.

Scribner B: Dialysis therapy in the United States: a historical perspective. **Home Hemodial Int** 1999;3:9–13.

Sehgal AR,Dor A,Tsai AC.Morbidity and cost implications of inadequate hemodialysis. **Am J Kidney Dis** 2001;37:1223–31.

Seitz W, Zimmer E, Alberti PE: Paper-electrophoretic studies on proteins in urine of normal and sick individuals [in German]. **Z Klin Med** 1953;152: 196 –201.

Shaldon S: development of hemodialysis , from access to machine (presentation given during a symposium entitled: excellence in dialysis :update in nephrology ; Karachi, Pakistan. October, 2002.

Shayamsunder AK, Patel SS, Jain V, Peterson RA, Kimmel PL. Sleepiness, sleepinessness, and pain in end-stage disease: distressing symptoms for patients. **Semin Dial**, 2005; 18: 109-18.

Shinzato T, Miwa M, Nakai S, Takai I, Matsumoto Y, Morita H, Miyata T, Maeda K: Alternate repetition of short fore- and back filtrations reduces convective albumin loss. **Kidney Int** 1996;**50**: 432–435.

Simmons EM, Himmelfarb J, Sezer MT, Chertow GM, Mehta RL, Paganini EP, Soroko S, Freedman S, Becker K, Spratt D, Shyr Y, Ikizler TA: Plasma cytokine levels predict mortality in patients with acute renal failure. **Kidney Int** 2004; **65**:1357–1365.

Slominska EM, Smolenski RT, Szolkiewicz M, Leaver N, Rutkowski B, Simmonds HA, Swierczynski J. Mol. Cell. Recent progress in the analysis of uremic toxins by mass spectrometry. **Biochem.** 2002; **231**: 83.

Smith JB, Shun SG, Sun Y, Miesbauer LR, Yang Z, Yang Z, Zhou X, Schwedler J, Smith DL. “Glutathione adducts, not carbamylated lysines, are the major modification of lens alphacrystallins from renal failure patients.” **J. Prot. Chem.** 1995; **14**, 179 – 188.

Sommer S, Berndt T, Craiq T et al., The phosphatonins and the regulation of phosphate transport and vitamin D metabolism. **J Steroid Mol Biol.** 2007; **103**(35):497-503.

Stange J, Mitzner S, Ramlow W, Glieshe T, Hickstein H, Schmidt R. A new procedure for the removal of protein bound drugs and toxins. **ASAIO J** 1993;**39**:621–5.

Stenvinkel P, Heimbürger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. **Am J Kidney Dis** 2002; 39:274-282.

Stenvinkel P. Inflammation in end-stage renal disease : the hidden enemy. **Nephrology** 2006; 11:36-41.

Suliman ME, Qureshi AR, Barany P, et al., hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. **Kid Int** 2000; 57(4): 1727-1735.

Sutton TA, Fisher JC, Molitoris BA: Microvascular endothelial injury and dysfunction during ischemic acute renal failure.**Kidney Int** 2002; 62:1539–1549.

Takeda N, Niwa T, Maeda K, Shibata M, Tatematsu A. “Rapid assay for indoxyl sulphate in uremic serum by internal-surface reversed-phase high-performance liquid chromatography.” **J. Chromatogr.** 1988, 431, 418 – 423.

Tattersall J, Martin-Malo A, Pedrini L, Basci A, Canaud B, Fouque D, Haage P, Konner K, Kooman J, Pizzarelli F, Tordoir J, Vennegoor M, Wanner C, Vanholder R. EBPG guideline on dialysis strategies. **Nephrol Dial Transplant** 2007;22[Suppl 2]: ii5–ii21.

Tepel M, van der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage

renal failure: a randomized controlled trial. **Circulation** 2003; 107(7): 992-995.

Tesch PE, Uremia: an overview. **Semin Nephrol.** 1994 May; 14(3):199-204.

Theodorescu D, Fliser D, Wittke S, Mischak H, Krebs R, Walden M, Ross M, Eltze E: Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. **Electrophoresis** 2005;26: 2797–2808.

Timothy W, Meyer and Thomas H. Hostetter. Review article: medical progress in uremia. **N. Engl J Med** 2007; 357: 1316-25.

Thornalley PJ. Recent progress in the analysis of uremic toxins by mass spectrometry. **Perit. Dial. Int.** 2005;25: 522.

Thornalley PJ, Argirova M, Ahmed N, Mann VM, Argirov O, Dawnay A. Recent progress in the analysis of uremic toxins by mass spectrometry. **Kidney Int.** 2000; 58: 2228.

Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, Dawnay A, Biochem. Recent progress in the analysis of uremic toxins by mass spectrometry. **J.** 2003;375: 581.

Tony Boure and Raymond Vanholder. Review article : biochemical and clinical evidence for uremic toxicity. **Artificial organ** 2004; 28(3):248-253.

Touam M, Zingraff J, Jungers P, Chadeaux-Vekemans B, Drueke T, Massy ZA. Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. **Kidney Int.** 1999; 56(6):2292–2296.

Tsutsumi Y, Deguchi T, Takano M, et al., Renal disposition of a furan dicarboxylic acid and other uremic toxins in the rat. **J Pharmal Exp Thr** 2002;303:880–887.

Ubbink JB, Vermaak WJH, et al., Vitamin B12 , vitamin B6, and folate nutritional status in men with hyperhomocysteinemia. **Am J Clin Nutr** 1993;57:47.

United States Renal Data Service. Excerpts from USRDS 2007 Annual Data Report. U.S. Department of Health and Human Services. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. **Am J Kidney Dis** 2008; 1(Suppl 1):S1.

Valli A, Suliman ME, Meert N, et al., Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. **Clin Chim Acta** 2007; 379:87-94.

Van Biesen W, Vanholder R, Veys N, Dhondt A, Lameire N: An evaluation of an integrative care approach for ESRD patients. **J Am Soc Nephrol** 2000;11:116–125.

Van Guldener C ,Janssen MJ: Folic acid treatment of Hyperhomocysteinemia in peritoneal dialysis patients: No change in endothelial function after long-term therapy . **Perit Dial Int** 1998;18:282-289.

Van Guldener C, Nanayakkara PW, Stehouwer CD. Review : Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease. **Clin Chem Lab Med.** 2007; Oct 15.

Van Laecke S, De Wilde K, and Vanholder R. Online Hemodiafiltration. **Artificial Organs** 2006;30(8):579-585.

Van Tellingen A, Grooteman MP, Bartels PC, Van Limbeek J, Van Guldener C, Wee PM, Nube MJ. Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients. **Kidney Int.** 2001; 59(1):342–347.

Vanholder R. Uremic toxins. **Adv Nephrol Necker Hosp.** 1997; 26: 143 -63.

Vanholder R. Back to the future: Middle molecules, High flux membranes, and optimal dialysis. **Hemodial Int** 2003d; 7:52-57.

Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML. Uremic toxicity: present state of the art. **Int J Artif Organs** 2001;24:695 725.

Vanholder RC and Ringoir SM: Adequacy of dialysis: A critical analysis. (editorial review) **Kidney Int** 1992a;42:540–558.

Vanholder R, De Deyn PP, Van Biesen W, Lameire N: Marconi revisited: from kidney to brain – two organ systems communicating at long distance. **J Am Soc Nephrol** 2008c;19:1253–1255.

Vanholder R, De Smet R, Schoots A, Ringoir S: Correlation of a colorimetric and a HPLC method for the determination of hippuric acid concentrations in uremia. **Nephron** 1988;49:164–168.

Vanholder R, De Smet RV, Ringoir SM. Assessment of urea and other uremic markers for quantification of dialysis efficacy. **Clin Chem.** 1992b; 38(8 Pt 1):1429–1436.

Vanholder R, De Smet R, Lesaffer G: p-Cresol: A toxin revealing many neglected but relevant aspects of uremic toxicity. **Nephrol Dial Transplant** 1999;14:2813-2815.

Vanholder R, De Smet R, Lesaffer G. Dissociation between dialysis adequacy and Kt/V. **Semin Dial.** 2002; 15(1):3–7.

Vanholder R, De Smet R, Glorieux G et al., Survival of Hemodialysis Patients and Uremic Toxin Removal. **Artificial Organs** 2003c;27 (3): 218–223.

Vanholder R, de Smet R, Glorieux G, Argile´s A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Joërrres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W:Review on uremic toxins: Classification, concentration, and interindividual variability. **Kidney Int** 2003b;63: 1934 –1943.

Vanholder R, Glorieux G, De Smet R, et al. New insights in uremic toxins. **Kidney Int 2003a**, 61(Suppl 84):S6.

Vanholder R, Glorieux GL, De Smet R. Uremic Toxins: Removal with Different Therapies. **Hemodial Int 2003e**; 7(2):162–167.

Vanholder R, Baurmeister U, Brunet P. A Bench to Bedside View of Uremic Toxins. **J Am Soc Nephrol 2008d**;19: 863–870.

Vanholder R, MeertN,Schepers E, Glorieux G, Argiles A, Brunet P, CohenG , Drueke T, Mishak H, Spasovski G, Massy Z, Jankowski J. Review on uraemic solutes II Variability in reported concentrations: causes and consequences. **Nephrol Dial Transplant 22 (2007); (11): 3115–3121.**

Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N: Chronic kidney disease as cause of cardiovascular morbidity and mortality. **Nephrol Dial Transplant 2005**;20: 1048 –1056.

Vanholder R, Schepers E, Meert N et al., What is uremia? retention versus oxidation. **Blood purif 2006**; 24:33-38.

Vanholder R, Van Laecke S, Glorieux G: What is new in uremic toxicity? **Pediatr Nephrol 2008a**;23:1211–1221.

Vanholder R, Van Laecke S, Verbeke F et al., Uremic toxins and cardiovascular disease: in vitro research versus clinical outcome studies **NDT Plus 2008b**; 1(1):2-10.

Vignes JR, Eimer S, Dupuy R, et al., β 2-microglobulin amyloidosis caused spinal cord compression in a long-term hemodialysis patients. **Spinal Cord.** 2007;45(4):322-6.

Wang W, Zhou H, Lin H, Roy S, Shaler TA, Hill LR, Norton S, Kumar P, Anderle M, Becker CH: Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards. **Anal Chem** 2003;75: 4818 – 4826.

Ward RA: Protein-Leaking Membranes for Hemodialysis: A New Class of Membranes in Search of an Application? Department of Medicine, University of Louisville, Louisville, Kentucky. **J Am Soc Nephrol** 2005;16: 2421–2430.

Ward RA and Brinkley KA: A proteomic analysis of proteins removed by ultrafiltration during extracorporeal renal replacement therapy. **Contrib Nephrol** 2004;141: 280 –291.

Ward RA, Schmidt B, Hullin J, Hillebrand GF, Samtleben W. A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study. **J Am Soc Nephrol** 2000;11(12):2344–2350.

Weissinger EM, Kaiser T, Meert N, De Smet R, Walden M, Mischak H, Vanholder RC. Recent progress in the analysis of uremic toxins by mass spectrometry. **Nephrol. Dial. Transplant.** 2004;19: 3068.

Wernert V, Schaf O, Ghobarkar H, Denoyel R. Adsorption properties of zeolites for artificial kidney applications. **Microporous Mesoporous Mater.** 2005;83, 101–113.

Wilson PW, Kauppila LI, O'Donnell CJ et al. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. **Circulation** 2001; 103: 1529–1534.

Winchester JF and Audia PF. Extracorporeal Strategies for Removal of Middle Molecules. **Seminars in Dialysis** 2006;19(2):110-114.

Winchester, F.J., Ronco, C., Salsberg, J., Yousha, E., Brady, J.A., Cowgill, L.D et al., Sorbent augmented dialysis systems. **Contrib Nephrol** 2002;137, 170–180.

Witko-Sarsat V, Friedlander M, Capeillere-Blandin et al., Advanced glycation end-products as a novel marker of oxidative stress in uremia. **Kidney Int** 1996;49:1304-1313.

Wizermann V, Lotz C, Techert F: O-line haemodiafiltration versus low-flux haemodialysis. A prospective randomized study. **Nephrol Dial Transplant** 2000;15(Suppl 1):43-48.

Wolfe RA, Hulbert-Shearon TE, Ashby VB et al. Improvements in dialysis patient mortality are associated with improvements in urea reduction ratio and hematocrit, 1999 to 2002. **Am J Kidney Dis** 2005; 45: 127–135.

Woolf AS, Palmer SJ, Snow ML and Fine LG: creation of a functioning chimetric mammalian kidney. **Kidney Int** 1999; 38:991-997.

Woods HF, and Nadakumar M. Improved outcome for hemodialysis patients treated with high-flux membranes. **Nephrol Dial Transplant** 2000;15(Suppl 1):36-42.

Xiang G, Schinzel R, Simm A, Sebekova K, Heidland A: Advanced glycation end products impair protein turnover in LLC-PK1: amelioration by trypsin. **Kidney Int** 2001;78:S53–S57.

Yamagishi S, Fujimori H, Yonekura H, Tanaka N, Yamamoto H. Advanced glycation endproducts accelerate calcification in microvascular pericytes. **Biochem Biophys Res Commun** 1999; 258: 353–357.

Yavuz A, Tetta C, Ersoy F, Bonello M. Division of Nephrology and Transplantation, Akdeniz University, Antalya, Turkey; Research Extracorporeal Therapies, Fresenius Medical Care Deutschland GmbH, Hamburg, Germany; Department of Nephrology, San Bortolo Hospital, Vicenza, Italy; and Renal Research Institute and Beth Israel Medical Center, New York, **New York Seminars in Dialysis—Vol 18, No 3 (May–June) 2005; pp. 203–211.**

Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. **Am J Kidney Dis**, 2000; 35: 469-76.

Yi Pan MD. Medicine Specialities > Neurology > Neurotoxicology > Uremic Neuropathy; **Article Last Updated: Oct 11, 2006.**

Zahedi K, Wang Z, Barone S, Prada AE, Kelly CN, Casero RA, Yokota N, Porter CW, Rabb H, Soleimani M: Expression of SSAT, a

novel biomarker of tubular cell damage, increases in kidney ischemia reperfusion injury. **Am J Physiol Renal Physiol** 2003;284:F1046–F1055.

Zhou H, Yuen PS, Pisitkun T, Gonzales PA, Yasuda H, Dear JW, Gross P, Knepper MA, Star RA: Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. **Kidney Int** 2006;69: 1471– 1476.

Zoccali C, Benedetto FA, Maas R et al., Asymetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. **J Am Soc Nephrol** 2002;13:490-496.

Zoccali C, Mallamaci F and Tripepi G. Novel Cardiovascular Risk Factors in End-Stage Renal Disease. **J.Am.Nephrol.** 2004; 15:S77-S80.

Zurbig P, Renfrow MB, Schiffer E, Novak J, Walden M, Wittke S, Just I, Pelzing M, Neususs C: Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. **Electrophoresis** 2006;27: 2111–2125.